CellFE announced the completion of a $22 million Series A financing led by M Ventures, with participation from Great Point Ventures, Riverine Ventures and its existing investors.
Exclusive: The California-based startup CellFE has raised a $22 million Series A to advance a new approach to making cell therapies with microfluidics.
The BIO International Convention (BIO) returns to in person meetings in San Diego, CA June 13-16 and CellFE will be there to present the…
CEO and Co-Founder Alla Zamarayeva PhD presented recently at the Startup Showcase at the ASGCT 25th Annual Conference.
Alla Zamarayeva, Co-Founder and CEO, has joined 10 women-led companies to participate in Springboard Enterprise’s 2022 Life Sciences Innovation Bootcamp.
CellFE, a microfluidics-based biotech startup based out of Alameda, CA, has recently had an article published in Scientific Reports.
CellFE will be presenting two posters at the American Society of Gene and Cell Therapy (ASGCT) 24th Annual Meeting next week occurring from May 11-14.
CellFE will be presenting a poster at the International Society of Gene and Cell Therapy (ISCT) Annual Meeting next week with a poster on Transfecting αβ T Cells with CRISPR-Cas9 RNP via microlfuidic method.
Todd Sulchek, PhD, Co-founder of CellFE and Head of the Sulchek BioMEMS & Biomechanics Lab at Georgia Tech, will be participating as a speaker…
Managing toxicity and specificity of cell therapies relies on complex gene-editing mechanisms, requiring co-delivery of multiple gene-editing molecules.
CellFE announced it has raised $3.6 million in an initial Series Seed, co-led by Cota Capital and Dynamk Capital, and joined by Embark Ventures.
CellFE will participate in one of 15 funded projects as part of $9M in funding by the National Institute for Innovation in Manufacturing Biopharmaceuticals…
